CNSP stock icon

CNS Pharmaceuticals


About: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Employees: 3

Funds holding %
of 6,689 funds
Analysts bullish %
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

19% more funds holding

Funds holding: 16 [Q4 2023] → 19 (+3) [Q1 2024]

6.15% more ownership

Funds ownership: 5.39% [Q4 2023] → 11.54% (+6.15%) [Q1 2024]

17% less capital invested

Capital invested by funds: $425K [Q4 2023] → $351K (-$74.3K) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for CNSP.

Financial journalist opinion

Based on 3 articles about CNSP published over the past 30 days